Plasma p-tau217 assays effectively predict amyloid status but lack precision for tau staging in Alzheimer's disease - PubMed
4 hours ago
- #Alzheimer's disease
- #P-tau217
- #Plasma biomarkers
- Plasma p-tau217 assays effectively predict amyloid status in Alzheimer's disease.
- These assays show high accuracy in distinguishing A+ from A-T- participants (AUC range: 0.85-0.91).
- Accuracy decreases when differentiating A+T+ from A+T- stages (AUC for p-tau217: 0.69-0.77).
- The study included 229 participants from the Alzheimer's Disease Neuroimaging Initiative.
- Findings were replicated in an independent cohort (n=334).
- Commercial plasma assays, including p-tau217, are less accurate in assessing tau pathology severity in Aβ positive individuals.